Schizophrenia Market

The Schizophrenia market is expected to increase with a CAGR of 6.89% for the study period 2017-2030 (in 7MM).

Schizophrenia affects approximately 20 million people worldwide. Around 30% of Schizophrenia patients are resistant to available antipsychotic drugs.

To bridge the broadening gaps in the treatment of Schizophrenia, several pharma and biotech companies such as Alkermes, Avineuro Pharma, Inc., Boehringer Ingelheim, Newron Pharma, Acadia Pharma, Minerva Neurosciences, BioXcel Therapeutics, Acadia Pharma, among several others are investigating their novel therapies.

For more details on Schizophrenia Market, visit: https://www.delveinsight.com/blog/schizophrenia-market/